Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Thyroid Gland Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 9 active trials
5 drugs · 3 active trials
10 drugs · 42 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 11 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Encorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 30, 2020 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| FOLFIRI Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 18, 2023 |
| Gemcitabine | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 18, 2023 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 14, 2024 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Panitumumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 18, 2023 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Sirolimus | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 27, 2017 |
| Tarlatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 8, 2025 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Cisplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-12 |
| Selumetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-12 |
| Alectinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 19, 2017 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-12 |
| Capecitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-12 |
| Doxorubicin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 13, 2013 |
| Imatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-02 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-10 |
| Tremelimumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Apr 25, 2017 |
| Abemaciclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 10, 2020 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-08 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-04 |
| Cediranib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 9, 2010 |
| Ceritinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-06 |
| Chemotherapy | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 28, 2020 |
| Dacarbazine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-12 |
| Decitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-05 |
| Denosumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 16, 2009 |
| Dexamethasone | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 23, 2016 |
| Dovitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-01 |
| Lenalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 9, 2010 |
| Lutetium (177lu) Oxodotreotide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 13, 2019 |
| Motesanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-07 |
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-05 |
| Panobinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-01 |
| Pasireotide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-11 |
| Ponatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 26, 2019 |
| Regorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-01 |
| Rovalpituzumab Tesirine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 23, 2016 |
| Sodium Iodide 131 I | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 15, 2021 |
| Tanespimycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-12 |
| Tovorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 15, 2021 |
| Vorinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-12 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.